<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338543</url>
  </required_header>
  <id_info>
    <org_study_id>2017-TCM-02</org_study_id>
    <nct_id>NCT03338543</nct_id>
  </id_info>
  <brief_title>PENS or TENS for Pain in Liver Cancer</brief_title>
  <official_title>Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and
      transcutaneous nerve stimulation (TENS) for pain relieving in patients with liver cancer.
      Patients will randomly allocated into PENS group, Tens group and control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PENS and TENS have been reported with analgesic effect in patients with pain, including
      cancer pain, lower back pain, neck pain, stomachache and so on. Effect and mechanism of PENS
      on pain relieving has been widely researched. With additional electrical stimulation in
      certain frequency and intensity to conventional acupuncture, pain controlling effect has been
      largely enhanced. However, invasive operation limits its application and acceptability,
      especially on pancreatic cancer. TENS is an advanced technique generated from PENS, which is
      much more welcome for its noninvasive character. Further more, its analgesic effect on cancer
      pain has been proved by several multi-central, randomized, clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients with liver cancer pain.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>pain score</measure>
    <time_frame>day0 to day6</time_frame>
    <description>pain score assessed via visual analogue scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantity of analgesic medication</measure>
    <time_frame>day0 to Day6</time_frame>
    <description>decreasing in quantity of analgesic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>times of breakthrough pain (BTP)</measure>
    <time_frame>day0 to day6</time_frame>
    <description>times of BTP per day</description>
  </secondary_outcome>
  <other_outcome>
    <measure>complications</measure>
    <time_frame>day1 to day3</time_frame>
    <description>any correlated complications happen during procedure</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pain</condition>
  <condition>Cancer Pain</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>percutaneous stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transcutaneous stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional analgesic medication is offered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PENS</intervention_name>
    <description>percutaneous electrical nerve stimulation</description>
    <arm_group_label>percutaneous stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>transcutaneous electrical nerve stimulation</description>
    <arm_group_label>transcutaneous stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary liver cancer with pain;

          -  Haven't underwent neurolytic celiac plexus block in the past 1 month;

          -  With anticipatory survival of more than 3 months.

        Exclusion Criteria:

          -  Metastatic liver cancer;

          -  Can not tolerate a flat or side lying or sitting prostrate for 30 min;

          -  performance score&gt;3;

          -  Who has been recruited in other clinical trial for pain relieving;

          -  Who underwent radiotherapy or local radioactive seeds implantation for pain relieving
             in the past month;

          -  Imaging diagnosed with encephalic tumor or metastasis;

          -  Who with cardiac pacemaker or metal stand;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihua He, Dr.</last_name>
    <phone>86-20-38993912</phone>
    <email>quincyhe@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuda Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua He, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006276. doi: 10.1002/14651858.CD006276.pub3. Review.</citation>
    <PMID>22419313</PMID>
  </reference>
  <reference>
    <citation>Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015 Jun 29;(6):CD009389. doi: 10.1002/14651858.CD009389.pub3. Review.</citation>
    <PMID>26121600</PMID>
  </reference>
  <reference>
    <citation>Chen H, Liu TY, Kuai L, Zhu J, Wu CJ, Liu LM. Electroacupuncture treatment for pancreatic cancer pain: a randomized controlled trial. Pancreatology. 2013 Nov-Dec;13(6):594-7. doi: 10.1016/j.pan.2013.10.007. Epub 2013 Oct 23.</citation>
    <PMID>24280575</PMID>
  </reference>
  <reference>
    <citation>Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015 Oct 15;(10):CD007753. doi: 10.1002/14651858.CD007753.pub3. Review.</citation>
    <PMID>26468973</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>percutaneous electrical nerve stimulation</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>pain</keyword>
  <keyword>liver cancer</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

